Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats
Abstract The therapeutic potential of (S)-Equol across various health domains, including mental health and oncology has been identified and studied enormously. However, the pharmacokinetic study on the enantiopure (S)-Equol in male and female rats under graded doses remain untouched, and the study c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-83901-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585848719147008 |
|---|---|
| author | Seethakallu Ramachandraiah AnandaKumar Mukund Handral Srinivas Seekallu |
| author_facet | Seethakallu Ramachandraiah AnandaKumar Mukund Handral Srinivas Seekallu |
| author_sort | Seethakallu Ramachandraiah AnandaKumar |
| collection | DOAJ |
| description | Abstract The therapeutic potential of (S)-Equol across various health domains, including mental health and oncology has been identified and studied enormously. However, the pharmacokinetic study on the enantiopure (S)-Equol in male and female rats under graded doses remain untouched, and the study concentrates on the same. Male and female CD(SD)IGS rats were grouped into 8 groups and some groups were administered with 20, 60 and 160 mg/kg body weight, orally and other administered with intravenous bolus injection at 10 mg/kg body weight of (S)-Equol. The plasma (S)-Equol concentrations were estimated by LC-MS/MS and the pharmacokinetic parameters determined from the concentration time data by non-compartmental PK analysis. The observed (S)-Equol Cmax was 66.78, 659.38, 2542.02 ng/mL in males and 392.08, 1661.97, 4879.36 in female rats, similarly, the observed (S)-Equol AUCLast was 118.96, 1130.32, 4876.00 h*ng/mL in males and 2164.01, 4883.09, 14067.94 in female rats at 20, 60 and 160 mg/kg dose respectively. The intravenous bolus administration of (S)-Equol showed 8563.25, 8642.91 ng/mL of Cmax and 3742.98, 3551.90 h*ng/mL AUCLast at 10 mg/kg dose in male and female rats respectively. The oral bioavailability of (S)-Equol was found to be 1.59, 5.03, 8.14% in male rats and 30.46, 22.91, 66.01% in female rats at doses of 20, 60 and 160 mg/kg of (S)-Equol administration respectively. These data suggesting that gender related differences in plasma exposure, increased plasma exposure was observed in female rats, plasma exposure at 60 mg/mL in female rats were comparable to the exposures at 160 mg/mL in males rats. |
| format | Article |
| id | doaj-art-72fe1ad5199c47fdb1d21afe3e543d97 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-72fe1ad5199c47fdb1d21afe3e543d972025-01-26T12:25:22ZengNature PortfolioScientific Reports2045-23222025-01-011511810.1038/s41598-024-83901-7Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS ratsSeethakallu Ramachandraiah AnandaKumar0Mukund Handral1Srinivas Seekallu2Department of Pharmacology, PESU Institute of Pharmacy, PES UniversityDepartment of Pharmacology, PESU Institute of Pharmacy, PES UniversityDepartment of Pre-Clinical Research, Anthem Biosciences Pvt. Ltd.Abstract The therapeutic potential of (S)-Equol across various health domains, including mental health and oncology has been identified and studied enormously. However, the pharmacokinetic study on the enantiopure (S)-Equol in male and female rats under graded doses remain untouched, and the study concentrates on the same. Male and female CD(SD)IGS rats were grouped into 8 groups and some groups were administered with 20, 60 and 160 mg/kg body weight, orally and other administered with intravenous bolus injection at 10 mg/kg body weight of (S)-Equol. The plasma (S)-Equol concentrations were estimated by LC-MS/MS and the pharmacokinetic parameters determined from the concentration time data by non-compartmental PK analysis. The observed (S)-Equol Cmax was 66.78, 659.38, 2542.02 ng/mL in males and 392.08, 1661.97, 4879.36 in female rats, similarly, the observed (S)-Equol AUCLast was 118.96, 1130.32, 4876.00 h*ng/mL in males and 2164.01, 4883.09, 14067.94 in female rats at 20, 60 and 160 mg/kg dose respectively. The intravenous bolus administration of (S)-Equol showed 8563.25, 8642.91 ng/mL of Cmax and 3742.98, 3551.90 h*ng/mL AUCLast at 10 mg/kg dose in male and female rats respectively. The oral bioavailability of (S)-Equol was found to be 1.59, 5.03, 8.14% in male rats and 30.46, 22.91, 66.01% in female rats at doses of 20, 60 and 160 mg/kg of (S)-Equol administration respectively. These data suggesting that gender related differences in plasma exposure, increased plasma exposure was observed in female rats, plasma exposure at 60 mg/mL in female rats were comparable to the exposures at 160 mg/mL in males rats.https://doi.org/10.1038/s41598-024-83901-7PharmacokineticBioavailabilityPlasma exposureBioanalysis |
| spellingShingle | Seethakallu Ramachandraiah AnandaKumar Mukund Handral Srinivas Seekallu Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats Scientific Reports Pharmacokinetic Bioavailability Plasma exposure Bioanalysis |
| title | Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats |
| title_full | Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats |
| title_fullStr | Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats |
| title_full_unstemmed | Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats |
| title_short | Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats |
| title_sort | bioavailability study of enantiopure s equol in cd sd igs rats |
| topic | Pharmacokinetic Bioavailability Plasma exposure Bioanalysis |
| url | https://doi.org/10.1038/s41598-024-83901-7 |
| work_keys_str_mv | AT seethakalluramachandraiahanandakumar bioavailabilitystudyofenantiopuresequolincdsdigsrats AT mukundhandral bioavailabilitystudyofenantiopuresequolincdsdigsrats AT srinivasseekallu bioavailabilitystudyofenantiopuresequolincdsdigsrats |